{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:38Z","timestamp":1753868678899,"version":"3.41.2"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C14\/18\/104"],"award-info":[{"award-number":["C14\/18\/104"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>CD19\u2010directed chimeric antigen receptor T\u2010cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia (BCP\u2010ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>Four patients with BCP\u2010ALL received tisagenlecleucel after second relapse (3\/4) or refractory disease at first relapse (1\/4). Three patients relapsed with CD19<jats:sup>NEG<\/jats:sup>\/CD22<jats:sup>POS<\/jats:sup> BCP\u2010ALL, one with CD19<jats:sup>POS<\/jats:sup>\/CD22<jats:sup>POS<\/jats:sup> BCP\u2010ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo\u2010HSCT and received palliative radiotherapy. This patient was in CR at the last follow\u2010up 25\u2009months later. The other patients were also in CR at the last follow\u2010up (mean 31.3\u2009months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>InO can be used successfully and safely for the treatment of CD22<jats:sup>POS<\/jats:sup> BCP\u2010ALL relapse after tisagenlecleucel as a bridge to allo\u2010HSCT in heavily pretreated pediatric patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.70177","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T17:24:21Z","timestamp":1741973061000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric <scp>BCP<\/scp>\u2010<scp>ALL<\/scp> After Tisagenlecleucel: A Case Series"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0734-380X","authenticated-orcid":false,"given":"Margo","family":"Aertgeerts","sequence":"first","affiliation":[{"name":"Department of Oncology KU Leuven  Leuven Belgium"},{"name":"Center for Cancer Biology VIB  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"Renard","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology UZ Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Uyttebroeck","sequence":"additional","affiliation":[{"name":"Department of Oncology KU Leuven  Leuven Belgium"},{"name":"Department of Pediatric Hematology and Oncology UZ Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Boeckx","sequence":"additional","affiliation":[{"name":"Department of Oncology KU Leuven  Leuven Belgium"},{"name":"Department of Laboratory Medicine UZ Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Segers","sequence":"additional","affiliation":[{"name":"Department of Oncology KU Leuven  Leuven Belgium"},{"name":"Department of Pediatric Hematology and Oncology UZ Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27624"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.554"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101768"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864\u2010021\u201000859\u20108"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03585"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01281-7"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01693"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01576-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01076"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0265-z"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16732"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011514"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284409"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007848"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:24:07Z","timestamp":1748363047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cnr2.70177"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70177","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70177"}}